The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study
出版年份 2019 全文链接
标题
The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study
作者
关键词
Dapagliflozin, Glycaemic control, Type 2 diabetes
出版物
DIABETOLOGIA
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2019-01-10
DOI
10.1007/s00125-018-4806-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- DECLARE-TIMI 58: Participants’ baseline characteristics
- (2018) Itamar Raz et al. DIABETES OBESITY & METABOLISM
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modelling cumulative exposure for inference about drug effects in observational studies
- (2017) Bassam Farran et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up
- (2017) J. Wilding et al. Primary Care Diabetes
- SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System
- (2017) Gian Paolo Fadini et al. Lancet Diabetes & Endocrinology
- Trends in type 2 diabetes incidence and mortality in Scotland between 2004 and 2013
- (2016) Stephanie H. Read et al. DIABETOLOGIA
- Real-World Evidence — What Is It and What Can It Tell Us?
- (2016) Rachel E. Sherman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study
- (2016) Michael A Weber et al. Lancet Diabetes & Endocrinology
- Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
- (2016) Juan P Frías et al. Lancet Diabetes & Endocrinology
- Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes
- (2015) Chantal Mathieu et al. DIABETES CARE
- Dapagliflozin Improves Glycemic Control and Reduces Body Weight as Add-on Therapy to Metformin Plus Sulfonylurea: A 24-Week Randomized, Double-Blind Clinical Trial
- (2015) Stephan Matthaei et al. DIABETES CARE
- Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
- (2015) Julio Rosenstock et al. DIABETES CARE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin
- (2014) M. A. Nauck et al. DIABETES OBESITY & METABOLISM
- The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials
- (2014) Yu-nan Sun et al. BMJ Open
- Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin
- (2013) John P.H. Wilding ANNALS OF INTERNAL MEDICINE
- Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
- (2013) Serge A. Jabbour et al. DIABETES CARE
- Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
- (2013) J. Bolinder et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
- (2013) Mei Zhang et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Urinary tract infections in patients with diabetes treated with dapagliflozin
- (2013) Kristina M. Johnsson et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
- (2012) J. Rosenstock et al. DIABETES CARE
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Assessment of the under-reporting of diabetes in hospital admission data: a study from the Scottish Diabetes Research Network Epidemiology Group
- (2011) H. Anwar et al. DIABETIC MEDICINE
- Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
- (2010) E. Ferrannini et al. DIABETES CARE
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
- (2010) Clifford J Bailey et al. LANCET
- A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment
- (2009) J. P.H. Wilding et al. DIABETES CARE
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
- (2008) J. F. List et al. DIABETES CARE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started